Potomac, Maryland, February 26, 2026 (Newswire.com) –
IGC Pharma, Inc. (NYSE American:IGC) (“IGC” or the “Company”)a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced the filing of a utility patent application covering the architectural framework for its internally developed AI-based data harmonization system, Agentic Harmonization Assistant (“AHA”).
IGC is developing AHA to support the standardization of disparate Alzheimer’s disease datasets, which often have widely varying schema definitions, variable encodings, and data structures. These discrepancies can limit cross-cohort analyzes and slow both clinical research and AI model development. AHA is designed as a structured, multi-stage agent architecture aimed at automating dataset alignment and validation across diverse Alzheimer’s disease datasets. The company has harmonized 15 Alzheimer’s disease-related datasets for internal development purposes and continues to refine its system architecture.
Earlier this year, AHA advanced to the semifinals of the Competitive AI Research and Assessment Program. The company plans to announce additional details about the AHA development roadmap at an upcoming ADPD conference.
The filed utility patent application is intended to protect key elements of AHA’s architectural design and harmonization methodology. IGC believes that scalable dataset harmonization infrastructure may become increasingly important in Alzheimer’s disease research as multi-cohort AI-powered analysis expands.
“While our primary focus remains on completing the CALMA clinical trial, we believe that scalable data harmonization and internal AI capabilities are essential to modern Alzheimer’s disease research,” said Ram Mukunda, CEO of IGC Pharma. “The AHA is being developed to support research initiatives and may support potential collaboration, integration, or licensing opportunities over time.”
About IGC Pharma (IDBA IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company that leverages AI to develop innovative treatments for Alzheimer’s disease and metabolic disorders. The Company’s lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial for Alzheimer’s disease agitation (CALMA). Our pipeline includes TGR-63, which targets amyloid plaques, and early-stage programs focused on neurodegeneration, tau protein, and metabolic dysfunction. Integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. IGC Pharma advances breakthrough treatments with a complete patent portfolio and commitment to innovation.
Forward-looking statements:
This press release contains forward-looking statements. These forward-looking statements are based primarily on IGC Pharma’s expectations and are subject to a number of risks and uncertainties, some of which are beyond IGC Pharma’s control. Actual results may differ materially from these forward-looking statements due to, among other things, our inability to commercialize or commercialize one or more of our products or technologies, including the products or formulations described in this release, our failure to obtain regulatory approval for our products or formulations, as required, or the failure of government regulations affecting AI or our AI algorithms to function as intended or produce accurate predictions. General economic conditions are less favorable than expected. FDA’s General Position on Cannabis and Hemp-Based Products. and other factors, many of which are described in IGC Pharma’s filings with the Securities and Exchange Commission (“SEC”). IGC incorporates by reference its annual reports on Form 10-K filed with the SEC on June 27, 2025, Form 10-Q filed with the SEC on August 14, 2025, and Form 10-Q filed with the SEC on November 14, 2025, as if fully incorporated and restated herein. Given these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will materialize. IGC Pharma, Inc. undertakes no obligation to update any forward-looking statements contained in this release as a result of new information, future events or developments.
contact address:
Rosalyn Christian / John Nesbett
IMS Investor Information
igc@imsinvestorrelations.com
(203) 972-9200
sauce: IGC Pharma Co., Ltd.
Source: IGC Pharma Co., Ltd.
